Dr. John H. Noseworthy is Chairman of the Digital Consortium, a collaboration between Aegis Ventures and health systems to collectively address healthcare’s most pressing quality, equity, and cost problems. He also serves as Executive Chair of Caire, a portfolio company which helps health systems connect patients to the right care at the right time, through an AI-enabled smart care platform.Dr. Noseworthy is also President and CEO Emeritus of Mayo Clinic, a not-for-profit organization operating in five states that is dedicated to medical care, research and education. Every year, more than a million people from all 50 states and nearly 130 countries come to Mayo Clinic for care.During Dr. Noseworthy’s tenure, Mayo became a leading global hub of healthtech innovation, the number-one ranked hospital in the world, and the number-one ranked location for destination medicine. Dr. Noseworthy served as a Health Governor of the World Economic Forum from 2012-2018.Dr. Noseworthy was previously a professor in the Department of Neurology. He specialized in multiple sclerosis and spent more than two decades designing and conducting controlled clinical trials with generous support from the Medical Research Council of Canada, the Multiple Sclerosis Society of Canada, the National Multiple Sclerosis Society (USA) and the National Institutes of Health. Dr. Noseworthy also is the author of more than 150 research papers, chapters, editorials and several books, including the three-volume textbook Neurological Therapeutics: Principles and Practice now in its second edition. He also served as editor-in-chief for Neurology, the official journal of the American Academy of Neurology.Prior to his appointment as Mayo Clinic’s CEO, Dr. Noseworthy served as chair of Mayo Clinic's Department of Neurology, medical director of the Department of Development, and vice chair of the Mayo Clinic Rochester Executive Board. His other board service includes current and past roles on the board of directors for Merck & Co., Inc., UnitedHealth Group, Inc., AlixPartners, The MITRE Corporation, and Tract Pharmaceuticals.